Trevor Allred
Stock Analyst at Oppenheimer
(4.73)
# 123
Out of 5,182 analysts
19
Total ratings
94.44%
Success rate
49.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Downgrades: Perform | n/a | $16.31 | - | 2 | Mar 5, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $275 → $277 | $228.48 | +21.24% | 9 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $83 → $81 | $71.67 | +13.02% | 2 | Feb 25, 2026 | |
| LEGN Legend Biotech | Initiates: Outperform | $75 | $23.99 | +212.63% | 1 | Jan 7, 2026 | |
| DSGN Design Therapeutics | Initiates: Outperform | $18 | $12.78 | +40.85% | 1 | Jan 7, 2026 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $80 | $33.39 | +139.59% | 2 | Sep 23, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $85 | $127.05 | -33.10% | 1 | Sep 9, 2025 | |
| INVA Innoviva | Initiates: Outperform | $35 | $23.48 | +49.06% | 1 | Aug 11, 2025 |
Theravance Biopharma
Mar 5, 2026
Downgrades: Perform
Price Target: n/a
Current: $16.31
Upside: -
Ligand Pharmaceuticals
Feb 27, 2026
Maintains: Outperform
Price Target: $275 → $277
Current: $228.48
Upside: +21.24%
BridgeBio Pharma
Feb 25, 2026
Maintains: Outperform
Price Target: $83 → $81
Current: $71.67
Upside: +13.02%
Legend Biotech
Jan 7, 2026
Initiates: Outperform
Price Target: $75
Current: $23.99
Upside: +212.63%
Design Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $18
Current: $12.78
Upside: +40.85%
MBX Biosciences
Sep 23, 2025
Maintains: Outperform
Price Target: $38 → $80
Current: $33.39
Upside: +139.59%
Palvella Therapeutics
Sep 9, 2025
Initiates: Outperform
Price Target: $85
Current: $127.05
Upside: -33.10%
Innoviva
Aug 11, 2025
Initiates: Outperform
Price Target: $35
Current: $23.48
Upside: +49.06%